Shares of Valeant Pharmaceuticals International Inc. fell 5% Monday after a Bloomberg report said the company’s former chief executive and former chief financial officer are the focus of a probe by U.S. prosecutors. Bloomberg reports that the case could bring charges in weeks. The former CEO, Michael Pearson, resigned in March 2016. Just prior to the release of the report the stock was trading down about 0.5%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News